EN / 中文
您的位置： 首页 > 2021年11月 第52卷 第6期 > 文字全文
2023年7月 第38卷 第7期11
目录

阿司匹林抗结直肠癌的作用机制的生物信息学分析

Bioinformatic analysis of mechanism of aspirin against colorectal cancer

来源期刊： 广州医药 | 23-34 发布时间：2021-11-26 收稿时间：2025/11/13 18:00:53 阅读量：29
作者：
郎吉萍,
戴秋月,
吕萍,
郭志刚,
关键词：
阿司匹林结直肠癌生物信息学细胞周期
aspirincolorectal cancerbioinformaticscell cycle
DOI：
10.3969/j.issn.1000-8535.2021.06.006
收稿时间：
2021-04-22 
修订日期：
 
接收日期：
 
引用总数：
0  
目的 通过生物信息学方法,分析阿司匹林抗结直肠癌的作用机制。方法 在DrugBank 5.1.5中查找阿司匹林的直接作用蛋白靶点(direct protein targets,DPTs);构建阿司匹林DPTs的蛋白质-蛋白质相互作用(protein-protein interaction,PPI)网络并分析相关信号通路;从GEO数据库中获取结直肠癌表达谱芯片数据,筛选中心度最高的20个结直肠癌差异表达基因作为Hub基因;将DPTs相互关联基因与结直肠癌Hub基因求交集,确认阿司匹林抗结直肠癌的潜在作用靶点,分析其在TCGA数据库结肠腺癌样本中的表达情况,并进行GO功能富集分析和KEGG信号通路分析。最终通过RT-PCR和WB实验验证阿司匹林抗结直肠癌的潜在靶点。结果 在DrugBank 5.1.5中确定了11个阿司匹林DPTs,KEGG信号通路分析发现其中6个DPTs(EDNRA,IKBKB,NFKB2,NFKBIA,PTGS2,TP53)与癌症的发生发展有关。将DPTs相关联基因与筛选的20个结直肠癌Hub基因求交集,发现5个基因(CDK1,AURKA,CCNB1,MAD2L1,TPX2)可能是阿司匹林抗结直肠癌的潜在作用靶点,其在TCGA数据库结肠腺癌样本中均表达上调,基因功能主要富集于细胞周期调控。RT-PCR和WB实验结果显示阿司匹林可以降低人结肠癌细胞中CDK1,AURKA,CCNB1,MAD2L1,TPX2的mRNA水平和蛋白表达。结论 CDK1,AURKA,CCNB1,MAD2L1,TPX2可能是阿司匹林抗结直肠癌的潜在靶点,其可能通过影响细胞周期调控发挥抗肿瘤作用。
Objective To analyze the mechanism of aspirin against colorectal cancer(CRC)by bioinformatic analysis. Methods DrugBank 5.1.5 was used to identify direct protein targets (DPTs) of aspirin. The protein-protein interaction (PPI) network of DPTs was constructed and involved signaling pathways were analyzed. CRC-associated gene expression datasets were downloaded from GEO database, and the top twenty differentially expressed genes with the highest degree were screened out as Hub genes. Common genes between the genes associated with the DPTs and the Hub genes of CRC were the potential targets of aspirin against CRC. The potential targets in TCGA database colon adenocarcinoma (COAD) samples were examined. GO functional enrichment analysis and KEGG signaling pathway analysis of the potential targets were performed. The potential targets of aspirin against CRC cells were verified by reverse transcription-polymerase chain reaction (RT-PCR) and western blot (WB). Results Eleven DPTs of aspirin were identified in DrugBank 5.1.5. KEGG signaling pathway showed that 6 genes (EDNRA, IKBKB, NFKB2, NFKBIA, PTGS2, TP53) were associated with the occurrence and development of CRC. By intersecting 20 Hub genes of CRC with genes associated with the DPTs of aspirin, it was found that 5 genes (CDK1, AURKA, CCNB1, MAD2L1, TPX2) might be the potential targets of aspirin against CRC. They were all up-regulated in TCGA-COAD samples, and the gene functions were mainly enriched in cell cycle regulation. The results of RT-PCR and WB showed that aspirin could down-regulate the mRNA and protein expression levels of CDK1, AURKA, CCNB1, MAD2L1 and TPX2 in human colon cancer cells respectively. Conclusion CDK1, AURKA, CCNB1, MAD2L1 and TPX2 could be potential targets of aspirin against CRC by affecting the progress of cell cycle regulation.
1、 CHEN X, SUN Y Z, ZHANG D H, et al. NRDTD: a database for clinically or experimentally supported non-coding RNAs and drug targets associations[J]. Database (Oxford), 2017(2017):bax057. CHEN X, SUN Y Z, ZHANG D H, et al. NRDTD: a database for clinically or experimentally supported non-coding RNAs and drug targets associations[J]. Database (Oxford), 2017(2017):bax057.
2、 ZHONG R, CHEN X, CHEN X, et al. MAD1L1 Arg558His and MAD2L1 Leu84Met interaction with smoking increase the risk of colorectal cancer[J]. Scientific Reports, 2015 (5):12202. ZHONG R, CHEN X, CHEN X, et al. MAD1L1 Arg558His and MAD2L1 Leu84Met interaction with smoking increase the risk of colorectal cancer[J]. Scientific Reports, 2015 (5):12202.
3、 LI Y, LI L, CHEN M, et al. MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradation[J]. Mol Oncol, 2018, 12(3):391-405. LI Y, LI L, CHEN M, et al. MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradation[J]. Mol Oncol, 2018, 12(3):391-405.
4、 ANJOMSHOA A A, LIN Y H, BLACK M A, et al. Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer[J]. Br J Cancer, 2008, 99(6):966-973. ANJOMSHOA A A, LIN Y H, BLACK M A, et al. Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer[J]. Br J Cancer, 2008, 99(6):966-973.
5、 AN B C, HONG S, PARK H J, et al. Anti-colorectal cancer effects of probiotic-derived p8 protein[J]. Genes (Basel), 2019, 10(8):624. AN B C, HONG S, PARK H J, et al. Anti-colorectal cancer effects of probiotic-derived p8 protein[J]. Genes (Basel), 2019, 10(8):624.
6、TAKAHASHI Y, SHERIDAN P, NIIDA A, et al. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC[J].Ann Oncol, 2015, 26(5):935-942.TAKAHASHI Y, SHERIDAN P, NIIDA A, et al. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC[J].Ann Oncol, 2015, 26(5):935-942.
7、 SILLARS-HARDEBOL A H, CARVALHO B, TIJSSEN M, et al. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression[J]. Gut, 2012, 61(11):1568-1575. SILLARS-HARDEBOL A H, CARVALHO B, TIJSSEN M, et al. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression[J]. Gut, 2012, 61(11):1568-1575.
8、 DACHINENI R, KUMAR D R, CALLEGARI E, et al. Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer[J]. Int J Oncol, 2017, 51(6):1661-1673. DACHINENI R, KUMAR D R, CALLEGARI E, et al. Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer[J]. Int J Oncol, 2017, 51(6):1661-1673.
9、 YANG J, XU W W, HONG P, et al. Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction[J]. Cancer Lett, 2019(451):79-91. YANG J, XU W W, HONG P, et al. Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction[J]. Cancer Lett, 2019(451):79-91.
10、 SUNG W W, LIN Y M, WU P R, et al. High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients[J]. BMC Cancer, 2014, 14(1):951. SUNG W W, LIN Y M, WU P R, et al. High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients[J]. BMC Cancer, 2014, 14(1):951.
11、 SESHAGIRI S, STAWISKI E W, DURINCK S, et al. Recurrent R-spondin fusions in colon cancer[J]. Nature, 2012, 488(7413):660-664. SESHAGIRI S, STAWISKI E W, DURINCK S, et al. Recurrent R-spondin fusions in colon cancer[J]. Nature, 2012, 488(7413):660-664.
12、 GIANNAKIS M, MU X J, SHUKLA S A, et al. Genomiccorrelates of immune-cell infiltrates in colorectal carcinoma[J]. Cell Rep, 2016, 15(4):857-865. GIANNAKIS M, MU X J, SHUKLA S A, et al. Genomiccorrelates of immune-cell infiltrates in colorectal carcinoma[J]. Cell Rep, 2016, 15(4):857-865.
13、 TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1):W98-W102. TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1):W98-W102.
14、 IWAYA T, YOKOBORI T, NISHIDA N, et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway[J]. Carcinogenesis, 2012, 33(12):2391-2397. IWAYA T, YOKOBORI T, NISHIDA N, et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway[J]. Carcinogenesis, 2012, 33(12):2391-2397.
15、 KHAMAS A, ISHIKAWA T, SHIMOKAWA K, et al. Screening for epigenetically masked genes in colorectal cancer using 5-Aza-2′-deoxycytidine, microarray and gene expression profile[J]. Cancer Genomics Proteomics, 2012, 9(2):67-75. KHAMAS A, ISHIKAWA T, SHIMOKAWA K, et al. Screening for epigenetically masked genes in colorectal cancer using 5-Aza-2′-deoxycytidine, microarray and gene expression profile[J]. Cancer Genomics Proteomics, 2012, 9(2):67-75.
16、 TSUKAMOTO S, ISHIKAWA T, IIDA S, et al. Clinical significance ofosteoprotegerin expression in human colorectal cancer[J]. Clin Cancer Res, 2011, 17(8):2444-2450. TSUKAMOTO S, ISHIKAWA T, IIDA S, et al. Clinical significance ofosteoprotegerin expression in human colorectal cancer[J]. Clin Cancer Res, 2011, 17(8):2444-2450.
17、 HONG Y, DOWNEY T, EU K W, et al. A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics[J]. Clin Exp Metastasis, 2010, 27(2):83-90. HONG Y, DOWNEY T, EU K W, et al. A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics[J]. Clin Exp Metastasis, 2010, 27(2):83-90.
18、 GAO J, AKSOY B A, DOGRUSOZ U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013, 6(269):pl1. GAO J, AKSOY B A, DOGRUSOZ U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013, 6(269):pl1.
19、 CERAMI E, GAO J, DOGRUSOZ U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5):401-404. CERAMI E, GAO J, DOGRUSOZ U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5):401-404.
20、 SHANNON P, MARKIEL A, OZIER O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003, 13(11):2498-2504. SHANNON P, MARKIEL A, OZIER O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003, 13(11):2498-2504.
21、 SZKLARCZYK D, MORRIS J H, COOK H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible[J]. Nucleic Acids Res, 2017, 45(D1):D362-D368. SZKLARCZYK D, MORRIS J H, COOK H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible[J]. Nucleic Acids Res, 2017, 45(D1):D362-D368.
22、 LIU Y, LIANG Y, WISHART D. PolySearch2: a significantly improved text-mining system for discovering associations between human diseases, genes, drugs, metabolites, toxins and more[J]. Nucleic Acids Res, 2015, 43(W1):W535-W542. LIU Y, LIANG Y, WISHART D. PolySearch2: a significantly improved text-mining system for discovering associations between human diseases, genes, drugs, metabolites, toxins and more[J]. Nucleic Acids Res, 2015, 43(W1):W535-W542.
23、 GONG L, ZHANG D, DONG Y, et al. Integratedbioinformatics analysis for identificating the therapeutic targets of aspirin in small cell lung cancer[J]. J Biomed Inform, 2018(88):20-28. GONG L, ZHANG D, DONG Y, et al. Integratedbioinformatics analysis for identificating the therapeutic targets of aspirin in small cell lung cancer[J]. J Biomed Inform, 2018(88):20-28.
24、 GOEL A, CHANG D K, RICCIARDIELLO L, et al. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells[J]. Clin Cancer Res, 2003, 9(1):383-390. GOEL A, CHANG D K, RICCIARDIELLO L, et al. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells[J]. Clin Cancer Res, 2003, 9(1):383-390.
25、 RANGER S, GURPREET. Therole of aspirin in colorectal cancer chemoprevention[J]. Crit Rev Oncol Hemat, 2016(104):87-90. RANGER S, GURPREET. Therole of aspirin in colorectal cancer chemoprevention[J]. Crit Rev Oncol Hemat, 2016(104):87-90.
26、 PATRIGNANI P, SACCO A, SOSTRES C, et al. Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer[J]. Clin Pharmacol Ther, 2017, 102(1):52-61. PATRIGNANI P, SACCO A, SOSTRES C, et al. Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer[J]. Clin Pharmacol Ther, 2017, 102(1):52-61.
27、 BIBBINS-DOMINGO K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force commendation statement[J]. Ann Int Med, 2016, 164(12): 836-845. BIBBINS-DOMINGO K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force commendation statement[J]. Ann Int Med, 2016, 164(12): 836-845.
28、 TADANOBU S, SHUSUKE T, KOMAROVA N L, et al. A comprehensive in vivo and mathematic modeling-based kinetic characterization for aspirin-induced chemoprevention in colorectal cancer[J]. Carcinogenesis, 2020, 41(6):751-760. TADANOBU S, SHUSUKE T, KOMAROVA N L, et al. A comprehensive in vivo and mathematic modeling-based kinetic characterization for aspirin-induced chemoprevention in colorectal cancer[J]. Carcinogenesis, 2020, 41(6):751-760.
29、 CHUBAK J, WHITLOCK E P, WILLIAMS S B, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force[J]. Ann Int Med, 2016, 164(12):814. CHUBAK J, WHITLOCK E P, WILLIAMS S B, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force[J]. Ann Int Med, 2016, 164(12):814.
30、 SANDLER R S, HALABI S, BARON J A, et al. A Randomized trial of aspirin to prevent colorectal adenomas in patients with previous[J]. N Engl J Med, 2003,348(10):883-890. SANDLER R S, HALABI S, BARON J A, et al. A Randomized trial of aspirin to prevent colorectal adenomas in patients with previous[J]. N Engl J Med, 2003,348(10):883-890.
31、 BENAMOUZIG R, UZZAN B, DEYRA J, et al. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial[J]. Gut, 2012, 61(2):255-261. BENAMOUZIG R, UZZAN B, DEYRA J, et al. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial[J]. Gut, 2012, 61(2):255-261.
32、 BARON J A, COLE B F, SANDLER R S, et al. A randomized trial of aspirin to prevent colorectal adenomas[J]. N Engl J Med, 2003, 348(10):891-899. BARON J A, COLE B F, SANDLER R S, et al. A randomized trial of aspirin to prevent colorectal adenomas[J]. N Engl J Med, 2003, 348(10):891-899.
33、 KATONA B W, WEISS J M. Chemoprevention of colorectal cancer[J]. Gastroenterology, 2020, 158(2):368-388. KATONA B W, WEISS J M. Chemoprevention of colorectal cancer[J]. Gastroenterology, 2020, 158(2):368-388.
34、 DREW D A, CAO Y, CHAN A T. Aspirin and colorectal cancer: the promise of precision chemoprevention[J]. Nat Rev Cancer, 2016, 16(3):173-186. DREW D A, CAO Y, CHAN A T. Aspirin and colorectal cancer: the promise of precision chemoprevention[J]. Nat Rev Cancer, 2016, 16(3):173-186.
35、 FENG R M, ZONG Y N, CAO S M, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Commun, 2019, 39(1):22. FENG R M, ZONG Y N, CAO S M, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Commun, 2019, 39(1):22.
36、 KEUM N, GIOVANNUCCI E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(12):713-732. KEUM N, GIOVANNUCCI E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(12):713-732.
37、 BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
上一篇
下一篇
作者登录
作者注册
审稿登录
编辑登录
最新资讯

“精神心理与脑科学：前沿与实践”专题征稿启事

发布于: 2026-05-29

“胶质瘤精准诊疗”专题征稿启事

发布于: 2026-05-29

“人工智能与医学融合”专题征稿启事

发布于: 2025-02-19

征稿 |《广州医药》—“医院管理”专栏征稿

发布于: 2025-01-21
学术活动

会议通知|人工智能赋能学科高质量发展专题讲座

发布于: 2025-02-19

广州市第一人民医院烧伤整形美容与创面修复科举办首期EWMA创面管理与修复培训班

发布于: 2026-05-29

提质增效，创新作为，不断提升麻醉服务能力2024工作总结与2025工作计划

发布于: 2025-02-19

2026年广州市医学会血液学分会学术年会暨再生障碍性贫血研讨会圆满落幕

发布于: 2026-06-01
出版者信息






《广州医药》公众号
目录
友情链接
关注微信公众号
首页   | 关于我们   | 联系我们  粤ICP备17084739号-3
关注微信公众号
粤ICP备17084739号-3